EUVIMEDEUVIMED entdecken
Systematische Übersicht

Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review

Mohammad Ghassab Deameh iD, Mohamed Ramez, Rashed Rowaiee, Baha' Aldeen Bani Irshid, Hamza Mohamed, Abdelrahman Abdelshafi, Mohammad Ali Al-Osoufi, Tarek Mohamed, Safa Botros Hegazin, Omer Raheem iD

The Journal of Sexual Medicine · 07.01.2026 · 23 (2)

DOI: 10.1093/jsxmed/qdaf381 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Journal of Sexual Medicine, online erschienen am 07.01.2026. Verfasst von Mohammad Ghassab Deameh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Faculty of Medicine, Al-Balqa Applied University, As-Salt 19117, Jordan. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Semen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are antidiabetic agents that also induce weight loss. Their widespread use has prompted investigation of potential benefits beyond glycemic control, including effects on male sexual and reproductive function. Emerging evidence suggests that they may improve male reproductive parameters, particularly in men with metabolic dysfunction.

Objectives

To systematically evaluate the effects of GLP-1RAs (liraglutide, semaglutide, dulaglutide, and exenatide) on male reproductive hormones, semen parameters, and metabolic outcomes.

Methods

We conducted a systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched in PubMed, Embase, Scopus, and Web of Science up to April 2025. Eligible studies included randomized controlled trials (RCTs) and cohort studies evaluating the effects of GLP-1RAs in adult men. Assessed the risk of bias with the risk of bias 2 tool for RCT and the Risk Of Bias In Non-Randomized Studies of Interventions (ROBINS-I) tool for observational studies.

Results

Ten studies involving a total of 639 men were included. GLP-1RAs were consistently associated with increased total testosterone, particularly in men with obesity, type 2 diabetes, or functional hypogonadism. Free testosterone changes were inconsistent, often offset by concurrent rises in sex hormone-binding globulin. Luteinizing hormone and follicle-stimulating hormone levels were preserved or increased with GLP-1RA use, in contrast to the suppression observed in testosterone therapy comparator groups. Improvements in semen parameters were reported in obese or hypogonadal men; however, no significant changes were found in healthy individuals.

Conclusion

GLP-1RAs may improve testosterone levels and potentially enhance semen quality in men with metabolic issues, while maintaining gonadotropin function. They could serve as fertility-sparing alternatives to testosterone therapy in some obesity-related hypogonadism cases. More long-term, controlled studies with standardized fertility measures are needed to confirm their role in male reproductive health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSemenHumansMaleSemaglutideTestosteroneExenatideSemen AnalysisGlucagon-Like PeptidesRecombinant Fusion ProteinsLiraglutideSex Hormone-Binding GlobulinLuteinizing HormoneImmunoglobulin Fc Fragments

Stichwörter der Autor:innen

GLP-1 agonistshypogonadismmale infertilitysemen analysistestosterone

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideTestosteroneExenatideHypoglycemic AgentsGlucagon-Like PeptidesdulaglutideRecombinant Fusion ProteinsLiraglutideSex Hormone-Binding Globulin

Autor:innen und Institutionen

  • Department of Urology, Faculty of Medicine, Al-Balqa Applied University, As-Salt 19117, Jordan.
  • Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • Department of Urology, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, UAE.
  • Department of Urology, Princess Basma Teaching Hospital, Irbid 21110, Jordan.
  • Department of Urology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
  • Department of Urology, Prince Hamzah Hospital, Amman 11947, Jordan.

ORCID-Profile: Mohammad Ghassab Deameh, Omer Raheem

Zitieren

APA

Deameh, M. G., Ramez, M., Rowaiee, R., Bani Irshid, B. A., Mohamed, H., Abdelshafi, A., Al-Osoufi, M. A., Mohamed, T., Hegazin, S. B., & Raheem, O. (2026). Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review. The Journal of Sexual Medicine, 23(2). https://doi.org/10.1093/jsxmed/qdaf381

Vancouver

Deameh MG, Ramez M, Rowaiee R, Bani Irshid BA, Mohamed H, Abdelshafi A, et al. Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review. The Journal of Sexual Medicine. 2026;23(2). doi:10.1093/jsxmed/qdaf381

BibTeX
@article{Deameh2026,
  author = {Deameh, Mohammad Ghassab and Ramez, Mohamed and Rowaiee, Rashed and Bani Irshid, Baha' Aldeen and Mohamed, Hamza and Abdelshafi, Abdelrahman and Al-Osoufi, Mohammad Ali and Mohamed, Tarek and Hegazin, Safa Botros and Raheem, Omer},
  title = {Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review},
  journal = {The Journal of Sexual Medicine},
  year = {2026},
  volume = {23},
  number = {2},
  doi = {10.1093/jsxmed/qdaf381}
}
Kostenlos starten →